FDA Adverse Event Injury Summary report: N

EX-PRESS MINI GLAUCOMA SHUNT

MDR report key: 2912972 · Received January 9, 2013

Report

Report Number
3003701944-2013-00002
Event Type
Injury
Date Received
January 9, 2013
Date of Event
January 1, 2012
Report Date
December 10, 2012
Manufacturer
OPTONOL, LTD.
Product Code
KYF
PMA / PMN Number
K030350
Removal / Correction Number
NA
Adverse Event
Yes
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
AR
Reporter Occupation
OTHER

Narratives

Additional Manufacturer Narrative · 1

THE PRODUCT WAS NOT RETURNED FOR ANALYSIS. THE PRODUCT HISTORY RECORDS COULD NOT BE REVIEWED BECAUSE THE REPORTER DID NOT PROVIDE A LOT NUMBER OR ANY IDENTIFICATION TRACEABLE TO THE MANUFACTURING DOCUMENTATION. THE PRODUCT INVESTIGATION COULD NOT IDENTIFY A ROOT CAUSE. NOT ENOUGH INFORMATION WAS PROVIDED FROM THE ACCOUNT TO PROPERLY COMPLETE AN INVESTIGATION. DR. EZEQUIEL A. SALVO, ALEJANDRO D. COUSSIO, SPONTANEOUS EXTRUSION OF AN EX-PRESS VALVE: A CASE REPORT, REFRACTIVA; 2012;34: 9-11. (B)(4).

Description of Event or Problem · 1

IN A JOURNAL ARTICLE, A SURGEON REPORTED A CASE OF A SPONTANEOUS EXTRUSION OF A SHUNT FOLLOWING AN UNCOMPLICATED PHACOTRABECULECTOMY SURGERY. DURING SUBSEQUENT MONITORING, THE INTRAOCULAR PRESSURE (IOP) WAS NOTED TO BE INCREASED. MASSAGES AND NEEDLINS WERE PERFORMED, MEDICATIONS GIVEN AND THE IOP WAS STABILIZED. TWO AND A HALF MONTHS FOLLOWING THE INITIAL SURGERY, THE SHUNT WAS OBSERVED TO BE MORE SUPERFICIAL THROUGH THE SCLERAL FLAP. THE SHUNT THEN EXTRUDED TOWARD THE EXTERIOR THROUGH THE SCLERAL FLAP AND CONJUNCTIVA AND WAS REMOVED SEVEN MONTHS AFTER THE INITIAL SURGERY. A PERIPHERAL IRIDECTOMY WAS ALSO PERFORMED WITH A YAG LASER DAYS AFTER THE REMOVAL OF THE SHUNT. TO DATE, THE PATIENT HAS STABLE INTRAOCULAR PRESSURE (IOP) AND IS BEING TREATED WITH ANTI-GLAUCOMATOUS DROPS.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
13169 EX-PRESS MINI GLAUCOMA SHUNT AQUEOUS SHUNT KYF OPTONOL, LTD. P-50 PL UNK

Patients

Seq Age Sex Outcome Treatment
1 69 YR Required Intervention DUOTRAV| GLAUCOTENSIL TD| IOL